What Is Allergy Shots? Definition, How They Work & Results

Allergy shots are most effective for IgE-mediated environmental allergies: allergic rhinitis (hay fever), allergic asthma, allergic conjunctivitis, and stinging insect venom allergy. A Cochrane review found them highly effective for grass pollen rhinitis, with AAAAI and ACAAI also supporting their use for dust mite, cat dander, and ragweed allergies. Venom immunotherapy is particularly powerful — 80–95% of sting-allergic patients are protected from future anaphylaxis after a full course of venom shots. Allergy shots are not used for food allergies, drug allergies, or non-IgE-mediated conditions. Your board-certified allergist will assess your specific sensitization profile and symptom severity to determine if you are a good candidate.

Most patients notice meaningful symptom improvement within 3 to 6 months of starting allergy shots — this corresponds to the early build-up phase when IgG4 blocking antibodies begin rising. Full therapeutic benefit typically develops over 12–18 months of consistent treatment, after which maintenance injections sustain the improvement. Some patients experience their first improvement during the first pollen season after starting shots. AAAAI guidelines recommend completing a full 3–5 year course for the best chance of lasting benefit after treatment ends. Patients who stop early may retain some benefit but are more likely to experience symptom return over time.

Allergy shots are not a one-time permanent cure, but for many patients the benefits last well beyond the treatment period. Research — including a landmark 1999 study by Durham et al. in the New England Journal of Medicine — found that grass pollen immunotherapy provided sustained benefit for 3 to 12 years after stopping treatment. The Preventive Allergy Treatment (PAT) study demonstrated that immunotherapy also prevents new allergen sensitizations and reduces the risk of asthma development in children treated for pollen allergy. Whether benefits persist long-term depends on individual immune response, allergen exposure, and whether a complete 3–5 year treatment course was completed.

Most patients describe allergy shots as less painful than a blood draw. The needle is 25–27 gauge — thinner than a standard venipuncture needle — and the injection goes into the subcutaneous fat of the posterior upper arm rather than into a vein or muscle. The sensation is typically a brief pinch lasting under five seconds. Local reactions — mild redness, swelling, and itching at the injection site — occur in 30–80% of patients at some point during treatment and are completely normal. Applying ice to the site after injection helps minimize discomfort. Systemic reactions (affecting the whole body) occur in only 0.1–0.2% of injections and are managed during the mandatory 30-minute observation period.

Yes — allergy shots are safe and effective for children, typically starting around age 5. The Preventive Allergy Treatment (PAT) study, published in the journal Allergy in 2007, demonstrated that immunotherapy not only reduces symptoms in children but also prevents new allergen sensitizations and significantly reduces the risk of developing asthma — a disease-preventing benefit that has important implications for long-term respiratory health. Pediatric allergy practices adjust injection volumes and sometimes use slightly faster dose escalation protocols compared to adults. The 30-minute observation requirement applies to children as well. Many allergists consider children with moderate-to-severe rhinitis that impairs school performance or sleep to be ideal candidates for immunotherapy.

Stopping allergy shots before completing the recommended 3–5 year maintenance course increases the likelihood of symptom return over time. Patients who complete only the build-up phase without sustained maintenance often experience some benefit in the short term, but the immune tolerance established during build-up is less durable without the reinforcement of regular maintenance doses. AAAAI guidelines suggest that the decision to stop should be made jointly with your allergist, typically after a minimum of 3–5 years of maintenance phase treatment. Some patients who stop after a complete course remain in remission for years; others experience gradual symptom return and may benefit from a second course of treatment.